BDX Earnings Preview: Becton Dickinson Reports May 7

Becton, Dickinson and Company (BDX) reports earnings on May 7, 2026, with analysts expecting $2.77 earnings per share and $4.67 billion in revenue. The medical device and diagnostics giant faces a critical test after mixed recent results. BDX stock trades at $144.17, down 1.46% today, reflecting broader healthcare sector pressure. Investors will scrutinize guidance and segment performance as the company navigates supply chain challenges and market competition. Meyka AI rates BDX with a grade of B+, signaling neutral positioning with balanced growth prospects and financial metrics.

What Analysts Expect from BDX Earnings

The consensus forecast shows BDX facing modest earnings pressure heading into this earnings report. Analysts project $2.77 EPS, representing a significant decline from the prior quarter’s $2.91 actual result reported in February 2026. Revenue estimates of $4.67 billion mark a notable pullback from the $5.25 billion achieved last quarter, suggesting seasonal weakness or market headwinds.

EPS Estimate Analysis

The $2.77 EPS estimate sits 4.8% below the previous quarter’s actual earnings. This decline signals analyst concerns about margin compression or operational challenges. Historically, BDX has shown volatility in quarterly performance, with Q3 2025 delivering $3.68 EPS, well above estimates. The current estimate reflects a more cautious outlook.

Revenue Forecast Breakdown

The $4.67 billion revenue estimate represents an 11% sequential decline from last quarter’s $5.25 billion. This contraction appears seasonal rather than structural, as BDX typically experiences Q2 softness. The estimate suggests flat to modest growth compared to year-ago periods, indicating market maturation in core segments.

Analyst Consensus Rating

Current analyst sentiment shows 3 Buy ratings, 7 Hold ratings, and 0 Sell ratings, reflecting cautious optimism. The consensus leans neutral, suggesting limited upside surprises expected. This mixed view reflects uncertainty about BDX’s ability to drive growth amid competitive pressures in medical devices and diagnostics.

Historical Earnings Trend and Beat/Miss Pattern

BDX has demonstrated an inconsistent earnings track record over recent quarters, with one significant beat and one miss pattern emerging. Understanding this history helps predict May 7 results.

Recent Quarter Performance

In February 2026, BDX beat EPS estimates by 31.7%, delivering $2.91 actual versus $2.21 estimated. Revenue also exceeded expectations, posting $5.25 billion versus $5.15 billion estimated. This strong beat suggested operational momentum and better-than-expected cost management. However, August 2025 showed similar outperformance with $3.68 EPS versus $3.40 estimated, indicating a pattern of conservative guidance.

Earnings Trend Direction

The three-quarter trend shows declining earnings momentum: Q3 2025 at $3.68, Q4 2025 at $2.91, and current estimates at $2.77. This downward trajectory reflects either seasonal factors or underlying business pressure. Revenue has also contracted sequentially, though year-over-year comparisons remain positive at approximately 8.2% growth.

Beat/Miss Prediction

Based on historical patterns, BDX has beaten EPS estimates in the last two reported quarters. The company appears to guide conservatively, creating upside surprises. Current $2.77 estimate may prove conservative, suggesting potential for a modest beat of 2-4%. However, revenue guidance will be critical—any miss there could offset EPS strength.

Key Metrics and What to Watch

Investors should focus on specific operational metrics and forward guidance when BDX reports May 7 results.

Segment Performance

BDX operates three main segments: BD Medical, BD Life Sciences, and BD Interventional. Watch for growth rates in each division, particularly Life Sciences diagnostics, which faces competition from larger players. Medical segment margins matter significantly given inflationary pressures on manufacturing costs. Interventional segment growth will indicate surgical market recovery.

Cash Flow and Dividend Sustainability

BDX maintains a 2.58% dividend yield with $3.73 dividend per share. Operating cash flow trends are critical—the company generated $11.91 per share trailing twelve months. Free cash flow of $9.23 per share supports the dividend and buybacks. Watch for any deterioration in cash generation, which could pressure the dividend.

Debt and Balance Sheet Health

BDX carries 0.77x debt-to-equity ratio, indicating moderate leverage. The company’s $52.2 billion market cap provides financial flexibility. Interest coverage of 4.81x remains adequate but not exceptional. Management commentary on debt reduction plans will signal financial priorities.

Guidance and Outlook

Forward guidance for fiscal 2026 will be crucial. Analysts will scrutinize management’s revenue growth expectations, margin targets, and capital allocation plans. Any reduction in full-year guidance could trigger stock weakness despite quarterly beat.

Meyka AI Grade and Investment Context

Meyka AI rates BDX with a grade of B+, reflecting balanced fundamentals with mixed growth signals. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests neutral positioning rather than strong conviction.

Grade Components Explained

The B+ grade combines strong valuation metrics with moderate growth concerns. BDX’s 23.55 P/E ratio sits above healthcare sector averages, reflecting premium positioning. However, 2.40x price-to-sales appears reasonable for a diversified medical device company. Return on equity of 6.93% trails sector leaders, indicating efficiency challenges. These factors balance to a neutral recommendation.

Technical Setup and Momentum

BDX shows oversold technical conditions with RSI at 29.92, suggesting potential bounce potential. However, strong downtrend with ADX at 33.83 indicates selling pressure remains intact. Stock has declined 11.2% over three months, creating valuation opportunity for long-term investors. Short-term traders should await earnings catalyst.

Risk Factors to Monitor

Key risks include competitive pressure from larger medtech peers, regulatory changes affecting device pricing, and supply chain disruptions. Geopolitical tensions could impact international sales, which represent significant revenue. Patent expirations on key products may pressure margins. These risks justify the neutral B+ rating rather than higher conviction.

Final Thoughts

BDX enters May 7 earnings with conservative guidance creating upside surprise potential. The $2.77 EPS estimate and $4.67 billion revenue forecast reflect seasonal weakness and competition. Meyka AI’s B+ grade reflects solid cash generation offset by slowing growth and margin pressure. Investors should focus on segment performance, cash flow trends, and forward guidance. The oversold technical setup and reasonable valuation offer opportunity for patient investors, though near-term catalysts remain limited. Watch management commentary on innovation and diagnostics market share trends.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.